DOI: 10.1038/NRD1752
关键词:
摘要: Immunologists have long hypothesized that particular 'molecular addresses' govern lymphocyte entry to a given organ. In 1992, α4β1 integrin was identified as the key molecule involved in homing inflamed regions of brain. An antibody α4β1integrin blocked paralysis an animal model multiple sclerosis, and humanized monoclonal natalizumab, which binds integrin, reduced relapses 66% clinical trials sclerosis. Three months after its expedited approval by FDA, natalizumab removed from market two cases deadly progressive multifocal leukoencephalopathy were reported among few thousand patients who had taken this drug those trials.